Related Experiment Video
Updated: May 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Metabolic complications of androgen deprivation therapy for prostate cancer
Philip J Saylor1, Matthew R Smith
1Department of Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit St., Boston, MA 02114, USA. psaylor@partners.org
Purpose:
Androgen deprivation therapy has a variety of well recognized adverse effects including vasomotor flushing, loss of libido, fatigue, gynecomastia, anemia and osteoporosis. This review focuses on the more recently described metabolic complications of androgen deprivation therapy including obesity, insulin resistance and lipid alterations as well as the association of androgen deprivation therapy with diabetes and cardiovascular disease.
Materials And Methods:
We reviewed the medical literature using the PubMed® search terms prostate cancer, androgen deprivation therapy, gonadotropin-releasing hormone agonists, obesity, insulin resistance, lipids, diabetes, cardiovascular disease and myocardial infarction. We provide a focused review and our perspective on the relevant literature.
Results:
Androgen deprivation therapy decreases lean mass and increases fat mass. It also decreases insulin sensitivity while increasing low density lipoprotein cholesterol, high density lipoprotein cholesterol and triglycerides. Consistent with these adverse metabolic effects, androgen deprivation therapy may be associated with a greater incidence of diabetes and cardiovascular disease. Some of these androgen deprivation therapy related metabolic changes (obesity, insulin resistance and increased triglycerides) overlap with features of the metabolic syndrome. However, in contrast to the metabolic syndrome, androgen deprivation therapy increases subcutaneous fat and high density lipoprotein cholesterol.
Conclusions:
Androgen deprivation therapy increases obesity, decreases insulin sensitivity and adversely alters lipid profiles. It may be associated with a greater incidence of diabetes and cardiovascular disease. The benefits of androgen deprivation therapy should be weighed against these and other potential harms. Little is known about the optimal strategy to mitigate the adverse metabolic effects of androgen deprivation therapy. Thus, we recommend an emphasis on existing strategies for screening and treatment that have been documented to reduce the risk of diabetes and cardiovascular disease in the general population.
Insights
Androgen deprivation therapy (ADT) increases obesity and insulin resistance, potentially raising risks for diabetes and cardiovascular disease. Healthcare providers should weigh ADT benefits against these metabolic harms and screen patients for related conditions.
Area of Science:
- Endocrinology
- Oncology
- Metabolic Syndrome
Background:
- Androgen deprivation therapy (ADT) is a cornerstone treatment for advanced prostate cancer.
- ADT is associated with numerous adverse effects, including well-known symptoms like hot flashes and fatigue.
- Emerging evidence highlights significant metabolic complications linked to ADT.
Purpose of the Study:
- To review the metabolic complications of ADT, focusing on obesity, insulin resistance, and lipid alterations.
- To examine the association between ADT and the increased incidence of diabetes and cardiovascular disease.
- To provide a focused review and expert perspective on the current literature regarding ADT's metabolic impact.
Main Methods:
- Comprehensive literature review using PubMed®.
- Search terms included "prostate cancer," "androgen deprivation therapy," "obesity," "insulin resistance," "lipids," "diabetes," and "cardiovascular disease."
- Focused review and synthesis of relevant findings and clinical perspectives.
Main Results:
- ADT leads to decreased lean mass and increased fat mass, contributing to obesity.
- ADT negatively impacts insulin sensitivity and alters lipid profiles, increasing LDL, HDL, and triglycerides.
- A potential association exists between ADT and a higher incidence of diabetes and cardiovascular events.
Conclusions:
- ADT adversely affects metabolic health by increasing obesity, reducing insulin sensitivity, and worsening lipid profiles.
- The potential for increased diabetes and cardiovascular disease incidence necessitates careful consideration of ADT's risks versus benefits.
- Further research is needed on optimal strategies to mitigate ADT-related metabolic adverse effects, emphasizing existing risk-reduction approaches for the general population.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Complications of Diabetes Mellitus
Menopause
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Diabetic Nephropathy
Chronic Kidney Disease II: Clinical Manifestations
